The global human growth hormone treatment and drugs market exhibits a valuation of US$ 3.55 Billion by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 3.7%, and is expected to hold a market value of around US$ 5.26 Billion in 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 3.55 Billion |
| Market Value 2023 | US$ 3.67 Billion |
| Market Value 2033 | US$5.26 Billion |
| CAGR 2023 to 2033 | 3.7% |
| Market Share of Top 5 Countries (2022) | 48.7% |
| Key Market Players | Ankebio Co. Ltd., Eli Lilly and Company, Emd Serono, Ferring Pharmaceuticals, Genentech Inc., Gene Science Pharmaceutical Co. Ltd., Ipsen, LG Life Sciences, Merck KGaA, Novo Nordisk, Ascendis Pharma, Pfizer Inc. |
Human growth hormone (hGH) also known as Somatotropin is a peptide hormone that is crucial for human development and is responsible for cell regeneration, cell reproduction, and growth stimulation. Growth hormone deficit results from the pituitary gland's inability to synthesise growth hormone (GH). Several inherited conditions, including Prader-Willi syndrome, Turner syndrome, and idiopathic short stature (ISS), which causes delayed puberty and shorter-than-average height, can also cause growth hormone insufficiency in humans.
Currently, hGH is frequently misused by bodybuilders, sportsmen, and older adults as an anti-aging medication and as a performance-enhancing anabolic substance. Growth hormone has not received USFDA approval for anti-aging or performance-enhancing uses because it is a prohibited substance.
Medication growth hormones are the suitable short-term treatments for such conditions, which are becoming more and more common among young people and elderly people alike worldwide. Medication for human growth hormone is readily available on the market today, raising awareness of its health benefits and helping manufacturing companies increase their revenue.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Human growth hormone treatment and drugs market expanded at a CAGR of 2.7% for 2017 to 2022 period due to growing incidences of growth hormone insufficiency, urban lifestyle and unhealthy food habits.
The market value for human growth hormone treatment and drugs was around 16.47% of the overall US$ 21.25 Billion of the global hormone replacement therapy market in 2022.
Due to increased research and development, increased healthcare expenditure, and improved healthcare infrastructure, the pharmaceutical and healthcare industries are rapidly expanding. Around the world, many hospitals, ambulatory surgical care centers, and clinics are installing cutting-edge devices and equipment.
Rising chronic disease prevalence, rapid advancements in the healthcare and medical sectors, widespread adoption of new tools and techniques, and increased funding from various public and private sectors are further, driving revenue growth in the global hormone replacement therapy market.
The advancement in human biomedical sciences and the discovery of new methods for synthesising long-acting second-generation products like growth hormones or somatotropin has brought down the human hormone growth injection price. This overall drop-in price has further boosted the growth of the human growth hormone treatment and drugs market globally.
Healthcare has undergone a digital revolution in the last decade. Rapid advancements in connected health, mobile technology, artificial intelligence (AI), and gamification, including virtual and augmented reality (VR/AR), are changing how patients are diagnosed, treated, and managed. Typically, digital health solutions are disease-specific and address specific conditions and patient populations.
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 2.50% |
| Jul-Dec (H2), 2021 (A) | 3.19% |
| Jan-Jun (H1),2022 Projected (P) | 2.40% |
| Jan-Jun (H1),2022 Outlook (O) | 2.64% |
| Jul-Dec (H2), 2022 Outlook (O) | 3.49% |
| Jul-Dec (H2), 2022 Projected (P) | 3.17% |
| Jan-Jun (H1), 2023 Projected (P) | 2.90% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 25 ↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 14 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 32 ↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (A) | 30 ↑ |
Principal Consultant
Urban lifestyles and deteriorating dietary habits leading to significant hormonal imbalance are expected to increase demand for human growth hormone drugs and a wide range of treatment options. Medication growth hormones assist in such situations and are thus, gaining popularity among both young and old people worldwide.
The market is further expected to grow due to a strenuous product pipeline and extensive research and development activities for the development of novel growth hormone therapies.
The market is also expected to be fuelled by a variety of public and private campaigns aimed at raising awareness of growth hormone deficiency and treatment options. The International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a non - profit organisation based in the United States, observes International Children's Growth Awareness Day each year to promote public understanding of the identification and management of growth hormone disorders and to aid in the rapid recovery of people, particularly children.
The use of growth hormone medication has been well established thanks to the efforts of healthcare sectors in every region. However, awareness to use of human growth hormones to treat many deficiency diseases among adults remains low, particularly in developing countries. This fact may significantly impede market participants from reaching their full potential.
In the market for treating growth hormone problems, complications are highly likely. Complications after the treatment include possible growth hormone therapy side effects, such as knee, hip, or other joint soreness; allergic reactions, such as hives, rash, or swelling; and an increase in blood sugar levels. As a result, it prevents the growth of the market.
The high cost of these medications restricts market expansion. Drugs for growth hormone disorders are expensive and may become costly for lower socioeconomic groups.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | The USA |
|---|---|
| Market Share (2023) | 25.9% |
| Market Share (2033) | 24.9% |
| BPS Analysis | -106 |
| Country | China |
|---|---|
| Market Share (2023) | 6.6% |
| Market Share (2033) | 6.8% |
| BPS Analysis | 19 |
| Country | Japan |
|---|---|
| Market Share (2023) | 5.9% |
| Market Share (2033) | 6.3% |
| BPS Analysis | 36 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.0% |
| Market Share (2033) | 4.6% |
| BPS Analysis | -38 |
| Country | Canada |
|---|---|
| Market Share (2023) | 4.9% |
| Market Share (2033) | 5.0% |
| BPS Analysis | 8 |
The USA is set to dominate the global human growth hormone treatment and drugs industry in 2023 with a market share of 25.9%.
The USA has a dominant position in the global market due to the presence of key players, primarily in the USA, who have expertise in manufacturing cutting-edge recombinant human growth hormone injections for the world's growing geriatric population.
According to the American Academy of Paediatrics, one in every 10,000 children in the USA suffers from growth hormone deficiency. Significant chronic and genetics conditions like Prader-Willi syndrome and Turner syndrome are rising. Thus, the increasing sale of growth hormone injections for the treatment of various growth disorders.
Germany is set to hold the largest sector share in Europe. Globally, Germany will hold around 5.0% revenue share in 2023.
The market for HGH medications in Germany is expected to grow due to a better understanding of growth hormonal diseases, a well-established health care infrastructure, and increased research and development, favorable reimbursement policies, and the region's established healthcare ecosystem.
According to the published article in the Deutsches Arzteblatt in 2011, Germany has developed a CrescNet System from last ten years in the Leipzig Treatment Center for early detection and awareness of growth hormone deficiency. Currently CrescNet System includes more than 323 medical practices and more than 22 pediatric endocrinology treatment centers with large number of doctors.
The China market will hold about 6.6% of the global market share in 2023.
The higher population count in China together with advanced research carried out in Chinese biotech companies are anticipated to boost the global market for Injectable human growth hormones at a higher growth rate.
According to a Biapharm in 2022 report, China has a large market for growth hormone products, which are required by around 7 million Chinese children for the treatment of short stature. HGH treatment for children is in high demand in China today, even when there is no medical abnormality. This has allowed domestic HGH manufacturers to expand while also attracting global pharmaceutical giants to the lucrative market.
Oral route of administration for leads the global market. In 2023, this segment is expected to hold about 43.3% within the global market.
Growth hormone deficiency in children is commonly perceived as a short height condition in boys and girls. Therefore, the human growth hormone pills for height are a popular oral product with huge growth potential during the forecast period.
The USA FDA (Food and Drug Administration) approved Macrilen (macimorelin) for oral administration in December 2017. This GH secretagogue receptor agonist is used to treat adult growth hormone deficiency (AGHD). Oral macimorelin administration is a simple, well tolerated, reproducible, and safe diagnostic test for AGHD, with the only reported side effect being bad taste.
Growth hormone deficiency (GHD) will lead the global market with the value share of about 27.7% in 2023.
As a broad category, growth hormone (GH) deficiency disease creates the most significant demand for human growth hormone shots in the healthcare sector. With the growing awareness among general population about the availability of treatment facilities and the discovery of new drugs, this segment is expected to hold the leading position for some more years ahead. Furthermore, GH deficiency in children is the major driving factor for this segment's human growth hormone treatment and drugs market.
Hospital pharmacies segment will hold the market share of 55.3% in 2023 globally.
Hormonal deficiency is a very serious concern for children and adults involves very complicated management of human growth hormone replacement therapy that skilled healthcare professionals in hospital setups must carry out. Attributing to this reason, the hospital pharmacy is the largest revenue generator for the global market accounting for more than about 50% of the stock volume of hGH human growth hormone injections for sale in the market.
Innovations in the field of designing new chemical formulations with greater efficiency is expected to increase the popularity of human growth hormone injections for adults in the market benefitting the market players. Key players within this space actively approaching mergers and acquisitions to expand their market reach and increase the volume of human growth hormone injections.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the human growth hormone treatment and drugs market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa. |
| Key Market Segments Covered | Route of Administration, Application, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is expected to be valued at US$ 3.55 billion in 2023.
Until 2033, the market may rise at a 3.7% CAGR.
By 2033, the market may total around US$ 5.26 billion.
Sedentary lifestyle drives market expansion.
North America is expected to dominate the market until 2033.
1. Executive Summary | Human Growth Hormone Treatment and Drugs Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends
4. Key Success Factors
4.1. Key Promotional Strategies, by Manufacturers
4.2. Key Regulations
4.3. PESTEL Analysis
4.4. Porter’s Analysis
4.5. Pipeline Assessment
4.6. Reimbursement
4.7. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Hormone Replacement Therapy Overview
5.2. Forecast Factors - Relevance and Impact
5.2.1. Top Companies Historical Growth
5.2.2. New Drug Launches and Approvals
5.2.3. Global Hormonal Diseases Epidemiology
5.2.4. RandD Expenditure by Key Players
5.2.5. Historic and Current Revenue of key players
5.2.6. Rising Consumer Awareness of the Treatment and Drugs
5.2.7. Increased Adoption of Hormonal Replacement Therapy for Various Hormonal Diseases
5.2.8. Strategic Collaborations among Players
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Route of Administration
6.1.2. By Application
6.1.3. By Distribution Channel
6.1.4. By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis by Route of Administration, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Route of Administration, 2023 to 2033
8.3.1. Subcutaneous
8.3.2. Intramuscular
8.3.3. Intravenous
8.3.4. Oral
8.4. Market Attractiveness Analysis by Route of Administration
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis by Application, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Application, 2023 to 2033
9.3.1. Growth Hormone Deficiency
9.3.2. Turner Syndrome
9.3.3. Idiopathic Short Stature (ISS)
9.3.4. Prader-Willi Syndrome (PWS)
9.3.5. Other Applications
9.4. Market Attractiveness Analysis by Application
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis by Distribution Channel, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Distribution Channel, 2023 to 2033
10.3.1. Hospital Pharmacy
10.3.2. Specialty Pharmacy
10.3.3. Retail Pharmacy
10.3.4. Online Pharmacy
10.4. Market Attractiveness Analysis by Distribution Channel
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, by Region, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. The Middle East and Africa
11.4. Market Attractiveness Analysis by Region
12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. The USA
12.3.1.2. Canada
12.3.2. By Route of Administration
12.3.3. BY Application
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Route of Administration
12.4.3. By Application
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis and Forecast
12.8.1. USA Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Route of Administration
12.8.1.2.2. By Application
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Route of Administration
12.8.2.2.2. By Application
12.8.2.2.3. By Distribution Channel
13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Route of Administration
13.3.3. By Application
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Route of Administration
13.4.3. By Application
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis and Forecast
13.8.1. Mexico Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Route of Administration
13.8.1.2.2. By Application
13.8.1.2.3. By Distribution Channel
13.8.2. Brazil Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Route of Administration
13.8.2.2.2. By Application
13.8.2.2.3. By Distribution Channel
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Route of Administration
13.8.3.2.2. By Application
13.8.3.2.3. By Distribution Channel
14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. United Kingdom
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Route of Administration
14.3.3. By Application
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Route of Administration
14.4.3. By Application
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis and Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Route of Administration
14.8.1.2.2. By Application
14.8.1.2.3. By Distribution Channel
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Route of Administration
14.8.2.2.2. By Application
14.8.2.2.3. By Distribution Channel
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Route of Administration
14.8.3.2.2. By Application
14.8.3.2.3. By Distribution Channel
14.8.4. United Kingdom Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Route of Administration
14.8.4.2.2. By Application
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Route of Administration
14.8.5.2.2. By Application
14.8.5.2.3. By Distribution Channel
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Route of Administration
14.8.6.2.2. By Application
14.8.6.2.3. By Distribution Channel
14.8.7. Russia Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Route of Administration
14.8.7.2.2. By Application
14.8.7.2.3. By Distribution Channel
15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Route of Administration
15.3.3. By Application
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Route of Administration
15.4.3. By Application
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis and Forecast
15.8.1. China Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Route of Administration
15.8.1.2.2. By Application
15.8.1.2.3. By Distribution Channel
15.8.2. Japan Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Route of Administration
15.8.2.2.2. By Application
15.8.2.2.3. By Distribution Channel
15.8.3. South Korea Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Route of Administration
15.8.3.2.2. By Application
15.8.3.2.3. By Distribution Channel
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Route of Administration
16.3.3. By Application
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Route of Administration
16.4.3. By Application
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis and Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Route of Administration
16.8.1.2.2. By Application
16.8.1.2.3. By Distribution Channel
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Route of Administration
16.8.2.2.2. By Application
16.8.2.2.3. By Distribution Channel
16.8.3. Malaysia Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Route of Administration
16.8.3.2.2. By Application
16.8.3.2.3. By Distribution Channel
16.8.4. Thailand Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Route of Administration
16.8.4.2.2. By Application
16.8.4.2.3. By Distribution Channel
17. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Route of Administration
17.3.3. By Application
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Route of Administration
17.4.2. By Application
17.4.3. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis and Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Route of Administration
17.8.1.2.2. By Application
17.8.1.2.3. By Distribution Channel
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Route of Administration
17.8.2.2.2. By Application
17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Türkiye
18.3.1.3. North Africa
18.3.1.4. South Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Route of Administration
18.3.3. By Application
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Route of Administration
18.4.3. By Application
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis and Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Route of Administration
18.8.1.2.2. By Application
18.8.1.2.3. By Distribution Channel
18.8.2. Türkiye Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Route of Administration
18.8.2.2.2. By Application
18.8.2.2.3. By Distribution Channel
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Route of Administration
18.8.3.2.2. By Application
18.8.3.2.3. By Distribution Channel
18.8.4. North Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Route of Administration
18.8.4.2.2. By Application
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Ankebio Co. Ltd.
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Sales Footprint
20.3.1.4. Key Financials
20.3.1.5. SWOT Analysis
20.3.1.6. Key Developments
20.3.1.7. Strategy Overview
20.3.1.7.1. Marketing Strategy
20.3.1.7.2. Product Strategy
20.3.1.7.3. Channel Strategy
20.3.2. Eli Lilly and Company
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Sales Footprint
20.3.2.4. Key Financials
20.3.2.5. SWOT Analysis
20.3.2.6. Key Developments
20.3.2.7. Strategy Overview
20.3.2.7.1. Marketing Strategy
20.3.2.7.2. Product Strategy
20.3.2.7.3. Channel Strategy
20.3.3. Emd Serono
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Sales Footprint
20.3.3.4. Key Financials
20.3.3.5. SWOT Analysis
20.3.3.6. Key Developments
20.3.3.7. Strategy Overview
20.3.3.7.1. Marketing Strategy
20.3.3.7.2. Product Strategy
20.3.3.7.3. Channel Strategy
20.3.4. Feeing Pharmaceuticals
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Sales Footprint
20.3.4.4. Key Financials
20.3.4.5. SWOT Analysis
20.3.4.6. Key Developments
20.3.4.7. Strategy Overview
20.3.4.7.1. Marketing Strategy
20.3.4.7.2. Product Strategy
20.3.4.7.3. Channel Strategy
20.3.5. Genentech Inc.
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Sales Footprint
20.3.5.4. Key Financials
20.3.5.5. SWOT Analysis
20.3.5.6. Key Developments
20.3.5.7. Strategy Overview
20.3.5.7.1. Marketing Strategy
20.3.5.7.2. Product Strategy
20.3.5.7.3. Channel Strategy
20.3.6. Gene Science Pharmaceutical Co. Ltd.
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Sales Footprint
20.3.6.4. Key Financials
20.3.6.5. SWOT Analysis
20.3.6.6. Key Developments
20.3.6.7. Strategy Overview
20.3.6.7.1. Marketing Strategy
20.3.6.7.2. Product Strategy
20.3.6.7.3. Channel Strategy
20.3.7. Ipsen
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Sales Footprint
20.3.7.4. Key Financials
20.3.7.5. SWOT Analysis
20.3.7.6. Key Developments
20.3.7.7. Strategy Overview
20.3.7.7.1. Marketing Strategy
20.3.7.7.2. Product Strategy
20.3.7.7.3. Channel Strategy
20.3.8. LG Life Sciences
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Sales Footprint
20.3.8.4. Key Financials
20.3.8.5. SWOT Analysis
20.3.8.6. Key Developments
20.3.8.7. Strategy Overview
20.3.8.7.1. Marketing Strategy
20.3.8.7.2. Product Strategy
20.3.8.7.3. Channel Strategy
20.3.9. Merck KGaA
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Sales Footprint
20.3.9.4. Key Financials
20.3.9.5. SWOT Analysis
20.3.9.6. Key Developments
20.3.9.7. Strategy Overview
20.3.9.7.1. Marketing Strategy
20.3.9.7.2. Product Strategy
20.3.9.7.3. Channel Strategy
20.3.10. Novo Nordisk
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Sales Footprint
20.3.10.4. Key Financials
20.3.10.5. SWOT Analysis
20.3.10.6. Key Developments
20.3.10.7. Strategy Overview
20.3.10.7.1. Marketing Strategy
20.3.10.7.2. Product Strategy
20.3.10.7.3. Channel Strategy
20.3.11. Ascendis Pharma
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Sales Footprint
20.3.11.4. Key Financials
20.3.11.5. SWOT Analysis
20.3.11.6. Key Developments
20.3.11.7. Strategy Overview
20.3.11.7.1. Marketing Strategy
20.3.11.7.2. Product Strategy
20.3.11.7.3. Channel Strategy
20.3.12. Pfizer Inc.
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Sales Footprint
20.3.12.4. Key Financials
20.3.12.5. SWOT Analysis
20.3.12.6. Key Developments
20.3.12.7. Strategy Overview
20.3.12.7.1. Marketing Strategy
20.3.12.7.2. Product Strategy
20.3.12.7.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Human Growth Hormone Treatment and Drugs Market
